{"full_title_en": "Mekhail Extension of the Motzer Score", "instructions_en": "", "search_abbreviation_en": ["mekhail", "ccf", "cleveland clinic foundation criteria", "RCC", "cleveland", "motzer", "face", "mikhail", "cleveland clinic", "CCF"], "calc_type": "diagnostic_criteria", "before_use": "", "cmeLastReviewed": null, "purpose_en": ["Prognosis"], "specialty_en": ["Hematology and Oncology", "Hospitalist Medicine", "Internal Medicine", "Nephrology", "Urology"], "slug": "mekhail-extension-motzer-score", "disease_en": ["Cancer", "Chemotherapy", "Renal Cell Carcinoma", "Renal Failure"], "cmeEndDate": null, "short_description_en": "Metastatic RCC survival.", "short_title_en": "Mekhail Extension", "medium_description_en": "Predicts metastatic renal cell carcinoma survival, more accurately than the Motzer Score.", "input_schema": [{"optional": false, "default": 0, "show_points": true, "conditionality": null, "name": "ldh", "tips_en": "Normal: 140 U/L", "label_en": "<p><abbr title=\"Lactate dehydrogenase\">LDH</abbr> &gt;1.5&times; upper limit of normal</p>", "type": "toggle", "options": [{"label": "No", "value": 0}, {"label": "Yes", "value": 1}]}, {"optional": false, "default": 0, "show_points": true, "conditionality": null, "name": "hgb", "tips_en": "Normal: <12 g/dL (120 g/L)", "label_en": "<p>Hemoglobin &lt;lower limit of normal</p>", "type": "toggle", "options": [{"label": "No", "value": 0}, {"label": "Yes", "value": 1}]}, {"optional": false, "default": 0, "show_points": true, "conditionality": null, "name": "ca", "tips_en": "", "label_en": "<p>Corrected serum calcium &gt;10 mg/dL (2.5 mmol/L)</p>", "type": "toggle", "options": [{"label": "No", "value": 0}, {"label": "Yes", "value": 1}]}, {"optional": false, "default": 0, "show_points": true, "conditionality": null, "name": "time", "tips_en": "", "label_en": "<p>Time from initial diagnosis to systemic treatment &lt;1 year</p>", "type": "toggle", "options": [{"label": "No", "value": 0}, {"label": "Yes", "value": 1}]}, {"optional": false, "default": 0, "show_points": true, "conditionality": null, "name": "radiation", "tips_en": "", "label_en": "<p>Prior treatment with radiation</p>", "type": "toggle", "options": [{"label": "No", "value": 0}, {"label": "Yes", "value": 1}]}, {"optional": false, "default": 0, "show_points": true, "conditionality": null, "name": "mets", "tips_en": "", "label_en": "<p>&ge;2 sites of metastasis</p>", "type": "toggle", "options": [{"label": "No", "value": 0}, {"label": "Yes", "value": 1}]}], "chief_complaint_en": ["Flank Pain", "Hematuria", "Mass"], "content": {"reviewer": {"expert_name": []}, "related_resources": {"interests": [{"link": "https://www.mdcalc.com/rcc-renal-cell-carcinoma-practice-pearls", "text": "Practice Pearls: Renal Cell Carcinoma", "description": ""}]}, "how_to_use": {"use_case_en": "<p>Patients with mRCC being considered for clinical trial enrollment.</p>", "pearls_pitfalls_en": "<p>This score placed clinical trial subjects from the 1970s-1990s with metastatic renal cell carcinoma (mRCC) into three groups with &ldquo;poor,&rdquo; &ldquo;intermediate,&rdquo; and &ldquo;favorable&rdquo; survival. There are no successful validations (later studies found different predictors), and the score may not apply to patients in common practice or those receiving modern targeted therapies such as sunitinib.</p>", "why_use_en": "<p>There are no validated scoring systems for predicting survival in mRCC. Using a score may help suggest categories of survival time better than clinical judgment alone.</p>"}, "next_steps": {"advice_en": "<p>The <calculator id=\"2153\">Motzer score</calculator> (which performs similarly with or without the Mekhail extension) is among the most commonly used for mRCC, and is probably best used for selecting patients to enroll in clinical trials. The score retrospectively identified variables associated with survival, which may ultimately help predict outcomes.</p>", "management_en": "<p>We are unaware of validated management algorithms using the score.</p>", "critical_actions_en": "<p>The <calculator id=\"2153\">Motzer score</calculator> (with or without the Mekhail extension) is not known to be accurate for individual survival prediction and should be considered a general guide rather than a concrete predictor.</p>"}, "about": {"formula_en": "<p><span>Addition of selected points:</span></p>\n<table>\n<tbody>\n<tr>\n<td>&nbsp;</td>\n<td>\n<p><strong>0 points</strong></p>\n</td>\n<td>\n<p><strong>1 point</strong></p>\n</td>\n</tr>\n<tr>\n<td>\n<p><strong>LDH &gt;1.5&times; upper limit of normal</strong></p>\n<p><span>Normal: 140 U/L</span></p>\n</td>\n<td>\n<p><span>No</span></p>\n</td>\n<td>\n<p><span>Yes</span></p>\n</td>\n</tr>\n<tr>\n<td>\n<p><strong>Hgb &lt;lower limit of normal</strong></p>\n<p><span>Normal: &lt;12 g/dL (120 g/L)</span></p>\n</td>\n<td>\n<p><span>No</span></p>\n</td>\n<td>\n<p><span>Yes</span></p>\n</td>\n</tr>\n<tr>\n<td>\n<p><strong>Corrected serum calcium &gt;10 mg/dL (3 mmol/L)</strong></p>\n</td>\n<td>\n<p><span>No</span></p>\n</td>\n<td>\n<p><span>Yes</span></p>\n</td>\n</tr>\n<tr>\n<td>\n<p><strong>Time from initial diagnosis to systemic treatment &lt;1 year</strong></p>\n</td>\n<td>\n<p><span>No</span></p>\n</td>\n<td>\n<p><span>Yes</span></p>\n</td>\n</tr>\n<tr>\n<td>\n<p><strong>Prior treatment with radiation</strong></p>\n</td>\n<td>\n<p><span>No</span></p>\n</td>\n<td>\n<p><span>Yes</span></p>\n</td>\n</tr>\n<tr>\n<td>\n<p><strong>&ge;2 sites of metastasis</strong></p>\n</td>\n<td>\n<p><span>No</span></p>\n</td>\n<td>\n<p><span>Yes</span></p>\n</td>\n</tr>\n</tbody>\n</table>\n<p><br><br></p>", "more_info_en": "<p>Criteria are the same as the <calculator id=\"2153\">Motzer Score</calculator>, with Karnofsky performance status excluded and with two additions:</p>\n<ol>\n<li>Prior treatment with radiation.</li>\n<li>&ge;2 sites of metastasis.</li>\n</ol>\n<p>Risk groups and correlated median survival also differ from the Motzer Score:</p>\n<table>\n<tbody>\n<tr>\n<td>\n<p><strong>Score</strong></p>\n</td>\n<td>\n<p><strong>Risk</strong></p>\n</td>\n<td>\n<p><strong>Median Survival</strong></p>\n</td>\n</tr>\n<tr>\n<td>\n<p><strong>0-1</strong></p>\n</td>\n<td>\n<p>Favorable</p>\n</td>\n<td>\n<p>28 months</p>\n</td>\n</tr>\n<tr>\n<td>\n<p><strong>2</strong></p>\n</td>\n<td>\n<p>Intermediate</p>\n</td>\n<td>\n<p>14 months</p>\n</td>\n</tr>\n<tr>\n<td>\n<p><strong>&ge;3</strong></p>\n</td>\n<td>\n<p>Poor</p>\n</td>\n<td>\n<p>5 months</p>\n</td>\n</tr>\n</tbody>\n</table>", "evidence_based_medicine_en": "", "references_list": {"Validation": [{"text": "Yildiz I, Sen F, Kilic L, et al. Prognostic factors associated with the response to sunitinib in patients with metastatic renal cell carcinoma. Curr Oncol. 2013;20(6):e546-53.", "href": "http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3851351/"}], "Outcomes": [], "Validations": [], "Original/Primary Reference": [{"text": "Mekhail TM, Abou-jawde RM, Boumerhi G, et al. Validation and extension of the Memorial Sloan-Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma. J Clin Oncol. 2005;23(4):832-41.", "href": "http://ascopubs.org/doi/full/10.1200/jco.2005.05.179"}], "Other References": [{"text": "Motzer RJ, Mazumdar M, Bacik J, Berg W, Amsterdam A, Ferrara J. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol. 1999;17(8):2530-40.", "href": "https://www.ncbi.nlm.nih.gov/pubmed/10561319 "}, {"text": "Motzer RJ, Bacik J, Murphy BA, Russo P, Mazumdar M. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 2002 Jan 1;20(1):289-96.", "href": "http://www.ncbi.nlm.nih.gov/pubmed/11773181"}], "Clinical Practice Guidelines": [], "Manufacturer Website": []}}, "creator": [{"qa_en": "", "approved": null, "name": "Dr. Tarek Mekhail", "creator_info": {"about_en": "<p><p>Tarek M. Mekhail, MD, MSc, is an associate professor of medicine at the University of Central Florida and the medical director of the Thoracic Oncology Program at the Florida Hospital Cancer Institute. Dr. Mekhail has been voted one of the Best Doctors in America in 2007-2008, 2008-2009 and 2009-2010. His research focuses on novel therapies and risk stratification in lung, kidney, and head/neck cancers.</p>", "photo_en": "https://cdn-web-img.mdcalc.com/people/dr-tarek-mekhail.jpeg", "pubmedLink": "http://www.ncbi.nlm.nih.gov/pubmed?term=mekhail%20tarek"}}], "contributor": {"expert_name": []}, "reviewers": []}, "system_en": ["Oncologic", "Renal", "Urinary"], "cmeReleaseDate": null, "dosing": false, "seo": {"meta_description_en": "The Mekhail Extension of the Motzer Score predicts metastatic renal cell carcinoma (RCC) survival, more accurately than the Motzer Score.", "keywords_en": "mskcc, mskcc score, rcc score, motzer score, mskcc motzer score, rcc prognosis, sloan kettering cancer score, sloan kettering cancer prognosis, sloan kettering rcc score, renal cell carcinoma score, mekhail extension, mekhail score, mekhail rcc, revised mskcc"}, "cmeVersion": null, "md5": "d949688031e2ac4a94b1be3f82da4069", "favorite_id": 3007, "related_calcs": [{"calcId": 2153, "short_title_en": "MSKCC/Motzer Criteria for RCC", "slug": "memorial-sloan-kettering-cancer-center-mskcc-motzer-score-metastatic-renal-cell-carcinoma-rcc"}, {"calcId": 3011, "short_title_en": "TNM RCC Staging", "slug": "tnm-staging-renal-cell-carcinoma"}, {"calcId": 3008, "short_title_en": "IMDC Model for mRCC", "slug": "imdc-international-metastatic-rcc-database-consortium-risk-model-metastatic-renal-cell-carcinoma"}]}